Properly scaled and targeted AAV2-NRTN (neurturin) to the substantia nigra is safe, effective and causes no weight loss: Support for nigral targeting in Parkinson's disease

by Raymond T. Bartus, Lamar Brown, Alistair Wilson, Brian Kruegel, Joao Siffert, Eugene M. Johnson, Jr., Jeffrey H. Kordower, Christopher D. Herzog
Published 2011-10-01

Enhanced neurotrophic distribution, cell signaling and neuroprotection following substantia nigral versus striatal delivery of AAV2-NRTN (CERE-120)

by Christopher D. Herzog, Lamar Brown, Brian R. Kruegel, Alistair Wilson, Malú G. Tansey, Fred H. Gage, Eugene M. Johnson, Jr., Raymond T. Bartus
Published 2013-10-01